Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
October 2014, Vol 5, No 8
October 2014, Vol 5 , No 8
CLEOPATRA: Record-Breaking Survival in HER2 Metastatic Breast Cancer by Adding Pertuzumab
By
Phoebe Starr
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with
HER2
-positive metastatic breast cancer.
Read Article
Medicaid Reimbursement Rate Has Direct Impact on Cancer Screening Rates
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
October 2014, Vol 5 , No 8
Although increasing the reimbursement rate for cancer screening tests does not consistently improve the likelihood of Medicaid beneficiaries being screened for cancer, raising the rate of reimbursement for office visits does consistently increase the likelihood that they will be screened for cancer, including breast or prostate cancer, according to results of a new analysis of Medicaid claims and enrollment data (Halpern MT, et al.
Cancer
. 2014 Aug 25. Epub ahead of print).
Read Article
Beleodaq (Belinostat) Receives FDA Approval for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
By
Lisa A. Raedler, PhD, RPh
Drug Updates
October 2014, Vol 5 , No 8
On July 3, 2014, the FDA approved belinostat (Beleodaq; Spectrum Pharmaceuticals) for the treatment of patients with relapsed or refractory PTCL.
Read Article
Cancer Support Community: Empowering Patients through Knowledge and Psychosocial Care
By
Wayne Kuznar
October 2014, Vol 5 , No 8
Los Angeles, CA—The advocacy community’s goal of patient-centered cancer care has evolved substantially over the past decade, said Kim Thiboldeaux, President and Chief Executive Officer of the Cancer Support Community (CSC), Washington, DC.
Read Article
Managing Cancer at the Workplace Enhances Productivity, Has Value for Employers
By
Wayne Kuznar
October 2014, Vol 5 , No 8
Los Angeles, CA—It is a good business decision to invest in better cancer management for employees with cancer, according to Lillie D. Shockney, RN, MAS, University Distinguished Service Associate Professor of Breast Cancer, Johns Hopkins Breast Center.
Read Article
Oncology Medical Home Pilot Improves Outcomes
By
Wayne Kuznar
October 2014, Vol 5 , No 8
Los Angeles, CA—Wilshire Oncology Medical Group President Linda D. Bosserman, MD, discussed the group practice’s oncology medical home pilot of value-based innovation at the Fourth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Does Comparative Effectiveness Research Have Value in Oncology?
By
Wayne Kuznar
Comparative Effectiveness Research
October 2014, Vol 5 , No 8
>Los Angeles, CA—Can comparative effectiveness research (CER) be used for determining value in cancer care? At the Fourth Annual Conference of the Association for Value-Based Cancer Care, C. Daniel Mullins, PhD, Chairman, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, discussed this topic on the challenges of applying CER into value-based oncology therapy.
Read Article
FDA Update - October 2014
FDA Approvals, News & Updates
October 2014, Vol 5 , No 8
FDA Approves New Combination Therapy, Akynzeo, for the Prevention of Nausea and Vomiting Associated with Chemotherapy
FDA Grants Priority Review for Palbociclib, a Novel Breast Cancer Drug
Read Article
Updated Management of Chronic Lymphocytic Leukemia
By
Alice Goodman
NCCN Congress Highlights
October 2014, Vol 5 , No 8
New York, NY—The FDA approvals of obinutuzumab (Gazyva), ofatumumab (Arzerra), ibrutinib (Imbruvica), and idelalisib (Zydelig) have changed the treatment paradigm of patients with chronic lymphocytic leukemia (CLL).
Read Article
Experts Debate the Role of Maintenance Rituximab in Follicular Lymphoma
By
Alice Goodman
NCCN Congress Highlights
October 2014, Vol 5 , No 8
New York, NY—In a debate on the role of rituximab (Rituxan) maintenance therapy in patients with follicular lymphoma at the 2014 National Comprehensive Cancer Network Congress, the protagonist and antagonist were not that far apart.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma